🇪🇺 IDegLira in European Union

EMA authorised IDegLira on 18 September 2014

Marketing authorisation

EMA — authorised 18 September 2014

  • Application: EMEA/H/C/002647
  • Marketing authorisation holder: Novo Nordisk A/S
  • Local brand name: Xultophy
  • Indication: Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.
  • Status: approved

Read official source →

IDegLira in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is IDegLira approved in European Union?

Yes. EMA authorised it on 18 September 2014.

Who is the marketing authorisation holder for IDegLira in European Union?

Novo Nordisk A/S holds the EU marketing authorisation.